"CAR T-Cell Therapy Shows Promise For Patients With Myeloma"
All patients with myeloma responded to treatment with BCMA-specific chimeric antigen receptor (CAR) T-cell therapy, according to results of an ongoing phase 1 trial. CAR t-cell therapies have demonstrated success in targeting B-cell biomarkers in clinical trial for acute lymphoblastic leukemia and lymphoma. "The utility of a treatment boils down to risk, benefit, cost, and quality of life. Speaking of cost, the advantage of CAR T-cell therapy is that it is a one-time intervention" says Ajai Chari, MD, associate professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai analyzing the results of the study. "If leading to a durable remission, although it may be expensive, it would be mitigated by the single-time intervention and durability of the response."
- Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai